Search Results

Drug development groups are close to discovering another pot of gold-a therapeutic target-similar to the success of imatinib (Gleevec) in the field of cancer biology. Modern molecular biology has improved cancer therapy through the identification of more pharmaceutically viable targets, and yet major problems and risks associated with late-phase cancer therapy remain. Presently, a growing number of reports have initiated a discussion about the benefits of metabolic regulation in cancers. The Warburg effect, a great discovery approximately 70 years ago, addresses the "universality" of cancer characteristics. For instance, most cancer cells prefer aerobic glycolysis instead of mitochondrial respiration. Recently, cancer metabolism has been explained not only by metabolites but also through modern molecular and chemical biological techniques. Scientists are seeking context-dependent universality among cancer types according to metabolic and enzymatic pathway signatures. This review presents current cancer metabolism studies and discusses future directions in cancer therapy targeting bio-energetics, bio-anabolism, and autophagy, emphasizing the important contribution of cancer metabolism in cancer therapy.
Autophagy ; Biology ; Glycolysis ; Metabolism* ; Molecular Biology ; Respiration ; Imatinib Mesylate

1.Exacerbation of Psoriasis after Imatinib Mesylate Treatment.

2.A Case of Lichenoid Drug Eruption Associated with Imatinib Mesylate.

3.Imatinib Mesylate-Induced Hyperpigmentation of the Nose and Palate.

4.Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor.

5.Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib.

6.Imatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib.

7.A High Risk Group in the Modified National Institutes of Health Consensus Criteria for the Gastrointestinal Stromal Tumor: A Clear Indication of the Adjuvant Imatinib.

8.Plantar Keratoderma with Pachyonychia Likely Induced by Imatinib Mesylate.

9.Lichenoid Drug Eruption after Low-Dose Imatinib Mesylate Treatment.

10.Cancer Metabolism: Strategic Diversion from Targeting Cancer Drivers to Targeting Cancer Suppliers.

Display Mode

Output Records

File Type